The following list of recent commissions gives a flavour of the services that Pleiad Europe provides for clients:

• Producing a detailed drug development plan for the EU and USA for a novel human therapeutic with additional potential uses as a veterinary therapeutic and a pesticide. The plan was used to form the basis of a round of equity financing and will now be utilised as the programme management tool.
• Writing a Phase III global drug development plan for an emerging pharmaceutical company.
• Management of a European clinical programme for a US client unable to manage the close-out stages themselves.
• Extensive market assessment undertaken for the development of a research park
• Writing a business plan including a product development plan, a market assessment and a company valuation for a company spun-out from a UK university.
• Producing a drug development plan to clinical proof of concept and a market assessment for a novel haematology technology, owned by a UK university, designed to inform the commercialisation strategy.
• Planning and management of a Phase II clinical programme in Europe for a US-based client.

In addition, Pleiad provides ongoing global drug development, strategic regulatory and medical/safety advice to numerous clients, as well as working with many academic and research institutions to assist them in the commercialisation of medical intellectual property.